ORGO vs. KMDA, CRMD, VRCA, VTYX, NLTX, VNDA, URGN, AVIR, PROC, and NKTX
Should you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Kamada (KMDA), CorMedix (CRMD), Verrica Pharmaceuticals (VRCA), Ventyx Biosciences (VTYX), Neoleukin Therapeutics (NLTX), Vanda Pharmaceuticals (VNDA), UroGen Pharma (URGN), Atea Pharmaceuticals (AVIR), Procaps Group (PROC), and Nkarta (NKTX). These companies are all part of the "pharmaceutical preparations" industry.
Kamada (NASDAQ:KMDA) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking.
Kamada has higher earnings, but lower revenue than Organogenesis. Kamada is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
Kamada has a net margin of 5.81% compared to Kamada's net margin of 1.14%. Organogenesis' return on equity of 5.66% beat Kamada's return on equity.
In the previous week, Kamada had 2 more articles in the media than Organogenesis. MarketBeat recorded 5 mentions for Kamada and 3 mentions for Organogenesis. Kamada's average media sentiment score of 0.27 beat Organogenesis' score of -0.26 indicating that Organogenesis is being referred to more favorably in the news media.
Kamada has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.
Kamada received 212 more outperform votes than Organogenesis when rated by MarketBeat users. However, 66.21% of users gave Organogenesis an outperform vote while only 64.98% of users gave Kamada an outperform vote.
Kamada presently has a consensus price target of $11.00, suggesting a potential upside of 91.64%. Organogenesis has a consensus price target of $4.83, suggesting a potential upside of 109.24%. Given Kamada's higher possible upside, analysts plainly believe Organogenesis is more favorable than Kamada.
20.4% of Kamada shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 34.0% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Kamada beats Organogenesis on 10 of the 18 factors compared between the two stocks.
Get Organogenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organogenesis Competitors List
Related Companies and Tools
